Figure 4 provides evidence of high BDP1 expression negatively impacting overall (Figure 4A) and progression‐free (Figure 4B) survival in serous ovarian cancer in samples containing TP53 mutations. This evidence concerns the gene BDP1 and ovarian serous adenocarcinoma.